These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 11485133)
1. Fatal fetal outcome with the combined use of valsartan and atenolol. Briggs GG; Nageotte MP Ann Pharmacother; 2001; 35(7-8):859-61. PubMed ID: 11485133 [TBL] [Abstract][Full Text] [Related]
2. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878 [TBL] [Abstract][Full Text] [Related]
3. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331 [TBL] [Abstract][Full Text] [Related]
4. Fetal toxicity of valsartan and possible reversible adverse side effects. Berkane N; Carlier P; Verstraete L; Mathieu E; Heim N; Uzan S Birth Defects Res A Clin Mol Teratol; 2004 Aug; 70(8):547-9. PubMed ID: 15329835 [TBL] [Abstract][Full Text] [Related]
5. Valsartan and atenolol in patients with severe essential hypertension. Cifkova R; Peleska J; Hradec J; Rosolová H; Pintérová E; Zeman K; Oddou-Stock P; Thirlwell J; Botteri F J Hum Hypertens; 1998 Aug; 12(8):563-7. PubMed ID: 9759992 [TBL] [Abstract][Full Text] [Related]
6. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Savoia C; Touyz RM; Volpe M; Schiffrin EL Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079 [TBL] [Abstract][Full Text] [Related]
7. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report]. Roger N; Popovic I; Madelenat P; Mahieu-Caputo D Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313 [TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. Fogari R; Zoppi A; Mugellini A; Corradi L; Lazzari P; Preti P; Derosa G J Cardiovasc Pharmacol; 2008 Mar; 51(3):217-22. PubMed ID: 18356684 [TBL] [Abstract][Full Text] [Related]
9. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Fogari R; Preti P; Derosa G; Marasi G; Zoppi A; Rinaldi A; Mugellini A Eur J Clin Pharmacol; 2002 Jun; 58(3):177-80. PubMed ID: 12107602 [TBL] [Abstract][Full Text] [Related]
10. Valsartan. Just a second-line antihypertensive drug. Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770 [TBL] [Abstract][Full Text] [Related]
11. Valsartan-induced angioedema. Irons BK; Kumar A Ann Pharmacother; 2003; 37(7-8):1024-7. PubMed ID: 12841812 [TBL] [Abstract][Full Text] [Related]
12. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Frampton JE; Scott LJ Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840 [TBL] [Abstract][Full Text] [Related]
13. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Boutouyrie P; Achouba A; Trunet P; Laurent S; Hypertension; 2010 Jun; 55(6):1314-22. PubMed ID: 20404219 [TBL] [Abstract][Full Text] [Related]
14. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548 [TBL] [Abstract][Full Text] [Related]
15. [Episodes of depression with attempted suicide after taking valsartan with hydrochlorothiazide]. Ullrich H; Passenberg P; Agelink MW Dtsch Med Wochenschr; 2003 Nov; 128(48):2534-6. PubMed ID: 14648436 [TBL] [Abstract][Full Text] [Related]
16. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Phipps JA; Wilkinson-Berka JL; Fletcher EL Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):927-34. PubMed ID: 17251496 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306 [TBL] [Abstract][Full Text] [Related]
18. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. Hollenberg NK; Parving HH; Viberti G; Remuzzi G; Ritter S; Zelenkofske S; Kandra A; Daley WL; Rocha R J Hypertens; 2007 Sep; 25(9):1921-6. PubMed ID: 17762658 [TBL] [Abstract][Full Text] [Related]
19. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157 [TBL] [Abstract][Full Text] [Related]